Mark Elliott Boulding, Exec. VP and CLO at Ptc Therapeutics, sold PTCT on Jul 6, 2026
Data as of Oct 16
- Traded
- Jul 6, 2026
- Disclosed
- Jul 8, 2026
- Filed
- 2 days after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
PTCT since disclosure
−33.1%
after the sale
Similar stocks (XLV) since disclosure
+8.9%
XLV — its sector index fund
Change in closing price from Jul 8, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.
Other trades in the same filing
- ▼ SELLMark Elliott Boulding Exec. VP and CLOPTCT Ptc Therapeutics, Inc.$70.3Kdisclosed Jul 8 · filed 2 days after the trade
- ▼ SELLMark Elliott Boulding Exec. VP and CLOPTCT Ptc Therapeutics, Inc.$32.2Kdisclosed Jul 8 · filed 2 days after the trade
- ▼ SELLMark Elliott Boulding Exec. VP and CLOPTCT Ptc Therapeutics, Inc.$64.4Kdisclosed Jul 8 · filed 2 days after the trade
- ▼ SELLMark Elliott Boulding Exec. VP and CLOPTCT Ptc Therapeutics, Inc.$87.4Kdisclosed Jul 8 · filed 2 days after the trade
- ▼ SELLMark Elliott Boulding Exec. VP and CLOPTCT Ptc Therapeutics, Inc.$51.9Kdisclosed Jul 8 · filed 2 days after the trade
- ▼ SELLMark Elliott Boulding Exec. VP and CLOPTCT Ptc Therapeutics, Inc.$26Kdisclosed Jul 8 · filed 2 days after the trade
- ▼ SELLMark Elliott Boulding Exec. VP and CLOPTCT Ptc Therapeutics, Inc.$44.6Kdisclosed Jul 8 · filed 2 days after the trade